Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

27 та иш

Иш: Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan

  1. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

    Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4

    Мақола201011 иқтибос
    ABI

  2. Global tuberculosis report (2014)

    L.A. Gabbasova, E.R. Experts Who

    Мақола20148 иқтибос
    ABI

  3. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

    Andrew Nunn, Patrick Phillips, Sarah Meredith +16

    Мақола20196 иқтибос
    ABI

  4. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

    Alberto Piubello, Souleymane Hassane Harouna, Mahamadou Bassirou Souleymane +5

    Мақола20146 иқтибос
    ABI

  5. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

    Christopher Kuaban, J Noeske, Hans L. Rieder +3

    Мақола20155 иқтибос
    ABI

  6. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

    Emanuele Pontali, Mario Raviǵlione, Giovanni Battista Migliori

    Шарҳ мақола20195 иқтибос
    ABI

  7. The Discovery of Grounded Theory; Strategies for Qualitative Research

    Barney G. Glaser, Anselm L. Strauss, Elizabeth Strutzel

    Мақола19685 иқтибос
    ABI

  8. Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

    Shona Horter, Beverley Stringer, Jane Greig +5

    МақолаTuberculosis Research and EpidemiologyBMC Infectious Diseases20164 иқтибос
    ABI

  9. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

    Faiz Ahmad Khan, M Salim, Philipp du Cros +9

    Шарҳ мақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20174 иқтибос
    ABI

  10. Principles for designing future regimens for multidrug-resistant tuberculosis

    Grania Brigden, Bern-Thomas Nyang’wa, Philipp du Cros +9

    Мақола20133 иқтибос
    ABI

  11. “When Treatment Is More Challenging than the Disease”: A Qualitative Study of MDR-TB Patient Retention

    Kalpita Shringarpure, Petros Isaakidis, Karuna D. Sagili +3

    Мақола20163 иқтибос
    ABI

  12. The Discovery of Grounded Theory: Strategies for Qualitative Research.

    Helmut R. Wagner, Barney G. Glaser, Anselm L. Strauss

    Мақола19683 иқтибос
    ABI

  13. ‘They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan

    Beverley Stringer, Karen Lowton, Mirzagaleb N. Tillashaikhov +5

    МақолаTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20162 иқтибос
    ABI

  14. Recent controversies about <scp>MDR</scp> and <scp>XDR‐TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDR‐TB</scp> regimen and bedaquiline for all with <scp>MDR‐TB</scp>?

    Keertan Dheda, Helen Cox, Aliasgar Esmail +3

    Шарҳ мақола20172 иқтибос
    ABI

  15. Sampling for qualitative research

    Martin Marshall

    Мақола19962 иқтибос
    ABI

  16. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis

    Ma Tarcela Gler, Laura Jean Podewils, N. Munez +3

    Мақола20122 иқтибос
    ABI

  17. Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness

    Carl May, David T. Eton, Kasey R. Boehmer +9

    Мақола20142 иқтибос
    ABI

  18. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

    Simon Tiberi, Nelita du Plessis, Gerhard Walzl +11

    Шарҳ мақола20182 иқтибос
    ABI

  19. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis

    Denise Rossato Silva, Margareth Pretti Dalcolmo, Simon Tiberi +9

    Шарҳ мақола20182 иқтибос
    ABI

  20. Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

    Giovanni Sotgiu, Simon Tiberi, Rosella Centis +4

    Мақола20162 иқтибос
    ABI

  21. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe

    Christoph Lange, Raquel Duarte, M. Jachym +7

    Бошқа20162 иқтибос
    ABI

  22. Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review

    Beena Thomas, Poonguzhali Shanmugam, Malaisamy Muniyandi +5

    Шарҳ мақола20162 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI